Press coverage about TrovaGene (NASDAQ:TROV) has trended somewhat positive on Friday, according to Accern. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TrovaGene earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.411573065432 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Stock’s Volume Buzz: TrovaGene, Inc. (NASDAQ:TROV), Bluerock Residential Growth REIT, Inc. (NYSE:BRG … (stocksnewspoint.com)
- Pitching Stocks: Verastem, Inc., (NYSE: VSTM), TrovaGene, Inc., (NYSE: TROV) (globalexportlines.com)
- US STOCKS ON THE MOVE-Apple, Trovagene, Capstone Turbine, Lumentum (nasdaq.com)
- US STOCKS ON THE MOVE-Trovagene, Monster Beverage, Apple, TapImmune (nasdaq.com)
- US STOCKS ON THE MOVE-Apple, Microsoft, Alibaba, Trovagene (nasdaq.com)
Shares of NASDAQ TROV traded down $0.85 during trading hours on Friday, reaching $0.92. 11,467,821 shares of the stock were exchanged, compared to its average volume of 259,767. The firm has a market cap of $9.20 million, a P/E ratio of -0.14 and a beta of -0.14. TrovaGene has a 52 week low of $0.78 and a 52 week high of $19.56.
TrovaGene (NASDAQ:TROV) last announced its earnings results on Tuesday, May 8th. The medical research company reported ($1.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.44) by $0.36. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. TrovaGene had a negative return on equity of 342.47% and a negative net margin of 3,861.57%. research analysts predict that TrovaGene will post -2.53 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on TROV shares. ValuEngine cut TrovaGene from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd. Zacks Investment Research cut TrovaGene from a “buy” rating to a “hold” rating in a research report on Thursday, May 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of TrovaGene in a research report on Tuesday, March 6th. Finally, Maxim Group reaffirmed a “hold” rating on shares of TrovaGene in a research report on Monday, April 16th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $19.17.
TrovaGene Company Profile
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.